{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:33:06Z","timestamp":1782156786641,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s13318-018-0495-5","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T10:16:53Z","timestamp":1531995413000},"page":"77-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduced Clearance of Phenobarbital in Advanced Cancer Patients near the End of Life"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9758-8004","authenticated-orcid":false,"given":"Hirokazu","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Echizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"495_CR1","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S1470-2045(12)70266-8","volume":"13","author":"M Weller","year":"2012","unstructured":"Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13:e375\u201382.","journal-title":"Lancet Oncol."},{"key":"495_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0885-3924(99)00006-8","volume":"17","author":"LC Stirling","year":"1999","unstructured":"Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manag. 1999;17:363\u20138.","journal-title":"J Pain Symptom Manag"},{"key":"495_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jpainsymman.2005.03.016","volume":"30","author":"T Morita","year":"2005","unstructured":"Morita T, Chinone Y, Ikenaga M, Miyoshi M, Nakaho T, Nishitateno K, et al. Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manag. 2005;30:308\u201319.","journal-title":"J Pain Symptom Manag"},{"key":"495_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp.43.4.365","volume":"43","author":"M Feely","year":"1980","unstructured":"Feely M, O\u2019Callagan M, Duggan B, Callaghan N. Phenobarbitone in previously untreated epilepsy. J Neurol Neurosurg Psychiatry. 1980;43:365\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"495_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/j.0013-9580.2004.12704.x","volume":"45","author":"P Kwan","year":"2004","unstructured":"Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004;45:1141\u20139.","journal-title":"Epilepsia."},{"key":"495_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239\u201376. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x\n                    \n                  .","journal-title":"Epilepsia."},{"key":"495_CR7","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/bcp.13259","volume":"83","author":"LG Franken","year":"2017","unstructured":"Franken LG, Masman AD, de Winter BCM, Baar FPM, Tibboel D, van Gelder T, et al. Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect? Br J Clin Pharmacol. 2017;83:1701\u201312. \n                    https:\/\/doi.org\/10.1111\/bcp.13259\n                    \n                  .","journal-title":"Br J Clin Pharmacol"},{"key":"495_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40262-015-0345-4","volume":"55","author":"LG Franken","year":"2016","unstructured":"Franken LG, Masman AD, de Winter BC, Koch BC, Baar FP, Tibboel D, et al. Pharmacokinetics of morphine, morphine-3-glucuronide and morphine-6-glucuronide in terminally ill adult patients. Clin Pharmacokinet. 2016;55:697\u2013709. \n                    https:\/\/doi.org\/10.1007\/s40262-015-0345-4\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"key":"495_CR9","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jcph.112","volume":"53","author":"T Naito","year":"2013","unstructured":"Naito T, Tashiro M, Ishida T, Ohnishi K, Kawakami J. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. J Clin Pharmacol. 2013;53:812\u20138.","journal-title":"J Clin Pharmacol"},{"key":"495_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00228-016-2116-z","volume":"72","author":"H Sato","year":"2016","unstructured":"Sato H, Naito T, Ishida T, Kawakami J. Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. Eur J Clin Pharmacol. 2016;72:1463\u201370.","journal-title":"Eur J Clin Pharmacol"},{"key":"495_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-014-1778-7","volume":"71","author":"K Vu\u010di\u0107evi\u0107","year":"2015","unstructured":"Vu\u010di\u0107evi\u0107 K, Jovanovi\u0107 M, Golubovi\u0107 B, Kova\u010devi\u0107 SV, Miljkovi\u0107 B, Martinovi\u0107 \u017d, et al. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. Eur J Clin Pharmacol. 2015;71:183\u201390.","journal-title":"Eur J Clin Pharmacol"},{"key":"495_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/FTD.0000000000000391","volume":"39","author":"H Nakayama","year":"2017","unstructured":"Nakayama H, Echizen H, Ogawa R, Akabane A, Kato T, Orii T. Induration at injection or infusion site may reduce bioavailability of parenteral phenobarbital administration. Ther Drug Monit. 2017;39:297\u2013302.","journal-title":"Ther Drug Monit"},{"key":"495_CR13","unstructured":"ARCHITECT\u00ae SYSTEM, Phenobarbital Package Insert. Abbott 2008. \n                    http:\/\/www.ilexmedical.com\/files\/PDF\/Phenobarbital_ARC.pdf\n                    \n                  . Accessed Aug 17, 2017."},{"key":"495_CR14","unstructured":"AXSYM\u00ae SYSTEM, Phenobarbital Package Insert. Abbott 2010. \n                    http:\/\/www.ilexmedical.com\/files\/PDF\/Phenobarbital_AXS.pdf\n                    \n                  . Accessed Aug 17, 2017."},{"key":"495_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1172\/JCI107647","volume":"53","author":"RA Branch","year":"1974","unstructured":"Branch RA, Shand DG, Wilkinson GR, Nies AS. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. J Clin Invest. 1974;53:1101\u20137.","journal-title":"J Clin Invest."},{"key":"495_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/j.1552-4604.1982.tb02662.x","volume":"22","author":"E Nelson","year":"1982","unstructured":"Nelson E, Powell JR, Conrad K, Likes K, Byers J, Baker S, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol. 1982;22:141\u20138.","journal-title":"J Clin Pharmacol"},{"key":"495_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.0013-9580.2005.47504.x","volume":"46","author":"S Messina","year":"2005","unstructured":"Messina S, Battino D, Croci D, Mamoli D, Ratti S, Perucca E. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data. Epilepsia. 2005;46:372\u20137.","journal-title":"Epilepsia."},{"issue":"139\u201346","key":"495_CR18","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jpainsymman.2015.03.004","volume":"50","author":"K Amano","year":"2015","unstructured":"Amano K, Maeda I, Shimoyama Shinjo T, Shirayama H, Yamada T, et al. The accuracy of physicians\u2019 clinical predictions of survival in patients with advanced cancer. J Pain Symptom Manag. 2015;50(139\u201346):e1. \n                    https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.03.004\n                    \n                  .","journal-title":"J Pain Symptom Manag"},{"key":"495_CR19","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/BF00191914","volume":"46","author":"I Bernus","year":"1994","unstructured":"Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Urinary excretion of phenobarbitone and its metabolites in chronically treated patients. Eur J Clin Pharmacol. 1994;46:473\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"495_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1440-1746.1996.tb00007.x","volume":"11","author":"J George","year":"1996","unstructured":"George J, Byth K, Farrell GC. Influence of clinicopathological variables on CYP protein expression in human liver. J Gastroenterol Hepatol. 1996;11:33\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"495_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/dmd.107.018747","volume":"36","author":"ET Morgan","year":"2008","unstructured":"Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36:205\u201316.","journal-title":"Drug Metab Dispos"},{"key":"495_CR22","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-10-3289","volume":"17","author":"M Kacevska","year":"2011","unstructured":"Kacevska M, Downes MR, Sharma R, Evans RM, Clarke SJ, Liddle C, et al. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin Cancer Res. 2011;17:3170\u201380.","journal-title":"Clin Cancer Res"},{"key":"495_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489\u201395. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7\n                    \n                  .","journal-title":"Lancet Oncol."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-018-0495-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0495-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-018-0495-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T18:23:44Z","timestamp":1567794224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-018-0495-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1007\/s13318-018-0495-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]},"assertion":[{"value":"19 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or non-profitable organizations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of the present study was approved by the Ethics Committee of NTT Medical Centre Tokyo (Reference No. 16-1319) prior to the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}